REGN – Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.REGN
$700.33Name : Regeneron Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $76,563,578,880.00
EPSttm : 38.31
Regeneron Pharmaceuticals, Inc.
$700.33
0.62%$4.31Float Short %
2.08
Margin Of Safety %
45
Put/Call OI Ratio
0.85
EPS Next Q Diff
-1.4
EPS Last/This Y
EPS This/Next Y
3.98
Price
700.66
Target Price
947.04
Analyst Recom
1.75
Performance Q
-8.09
Relative Volume
0.81
Beta
0.27
Ticker: REGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | REGN | 694.36 | 0.90 | 1.13 | 32357 |
| 2025-01-24 | REGN | 675.93 | 0.89 | 0.87 | 32819 |
| 2025-01-27 | REGN | 685 | 0.90 | 0.86 | 32758 |
| 2025-01-28 | REGN | 686.58 | 0.92 | 0.99 | 33360 |
| 2025-01-29 | REGN | 688.27 | 0.92 | 0.91 | 33602 |
| 2025-01-30 | REGN | 683.09 | 0.91 | 1.22 | 34166 |
| 2025-01-31 | REGN | 672.49 | 0.90 | 1.77 | 34563 |
| 2025-02-03 | REGN | 666.14 | 0.98 | 0.76 | 34551 |
| 2025-02-04 | REGN | 697.36 | 0.96 | 0.23 | 36781 |
| 2025-02-05 | REGN | 716.79 | 0.87 | 0.48 | 40113 |
| 2025-02-06 | REGN | 723.07 | 0.88 | 0.39 | 40459 |
| 2025-02-07 | REGN | 709.77 | 0.90 | 0.38 | 40553 |
| 2025-02-10 | REGN | 690.38 | 0.86 | 1.13 | 36364 |
| 2025-02-11 | REGN | 664.98 | 0.87 | 0.95 | 36905 |
| 2025-02-12 | REGN | 663.64 | 0.87 | 0.29 | 37702 |
| 2025-02-13 | REGN | 673.66 | 0.85 | 0.27 | 38299 |
| 2025-02-14 | REGN | 673.54 | 0.82 | 0.56 | 39126 |
| 2025-02-18 | REGN | 679.56 | 0.85 | 0.81 | 37675 |
| 2025-02-19 | REGN | 685.82 | 0.85 | 0.89 | 37955 |
| 2025-02-20 | REGN | 696.29 | 0.86 | 1.44 | 37993 |
| 2025-02-21 | REGN | 700.66 | 0.85 | 0.55 | 38339 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | REGN | 694.64 | -5.4 | 112.8 | 45.07 |
| 2025-01-24 | REGN | 675.47 | -5.2 | -159.4 | 45.07 |
| 2025-01-27 | REGN | 684.68 | -5.2 | 66.6 | 45.07 |
| 2025-01-28 | REGN | 686.27 | -5.3 | 6.2 | 45.07 |
| 2025-01-29 | REGN | 687.27 | -4.5 | 1.1 | 45.07 |
| 2025-01-30 | REGN | 683.08 | -3.8 | -40.3 | 45.07 |
| 2025-01-31 | REGN | 672.51 | -4.1 | -92.4 | 45.07 |
| 2025-02-03 | REGN | 666.85 | -5.5 | -183.8 | 45.07 |
| 2025-02-04 | REGN | 697.05 | -5.5 | 112.1 | 45.07 |
| 2025-02-05 | REGN | 716.71 | -5.5 | 685.9 | 43.62 |
| 2025-02-06 | REGN | 721.91 | -5.5 | -95.9 | 43.62 |
| 2025-02-07 | REGN | 709.69 | -5.5 | -91.1 | 43.75 |
| 2025-02-10 | REGN | 690.36 | -5.5 | -146.6 | 43.84 |
| 2025-02-11 | REGN | 664.86 | -5.5 | -195.8 | 43.84 |
| 2025-02-12 | REGN | 663.82 | -5.5 | -14.1 | 43.84 |
| 2025-02-13 | REGN | 674.27 | -5.5 | 82.0 | 43.20 |
| 2025-02-14 | REGN | 673.60 | -5.5 | -6.3 | 43.20 |
| 2025-02-18 | REGN | 679.82 | 0.5 | 47.8 | 43.20 |
| 2025-02-19 | REGN | 685.66 | 0.5 | 43.0 | 43.09 |
| 2025-02-20 | REGN | 696.42 | 0.5 | 81.8 | 43.09 |
| 2025-02-21 | REGN | 700.66 | 0.5 | 34.2 | 43.09 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | REGN | -0.86 | -1.17 | 1.98 |
| 2025-01-24 | REGN | -0.86 | -1.17 | 1.98 |
| 2025-01-27 | REGN | -0.86 | -1.25 | 1.98 |
| 2025-01-28 | REGN | -0.86 | -1.25 | 2.00 |
| 2025-01-29 | REGN | -0.86 | -1.25 | 2.00 |
| 2025-01-30 | REGN | -0.86 | -1.25 | 2.00 |
| 2025-01-31 | REGN | -0.86 | -1.25 | 2.00 |
| 2025-02-03 | REGN | -0.86 | -1.12 | 2.00 |
| 2025-02-04 | REGN | -0.86 | -1.12 | 2.00 |
| 2025-02-05 | REGN | -0.86 | -1.12 | 2.00 |
| 2025-02-06 | REGN | -0.81 | -1.12 | 2.00 |
| 2025-02-07 | REGN | -0.82 | -1.12 | 2.00 |
| 2025-02-10 | REGN | -0.81 | -1.10 | 2.01 |
| 2025-02-11 | REGN | -0.79 | -1.10 | 2.01 |
| 2025-02-12 | REGN | -0.78 | -1.10 | 2.08 |
| 2025-02-13 | REGN | -0.66 | -1.10 | 2.08 |
| 2025-02-14 | REGN | -0.67 | -1.10 | 2.08 |
| 2025-02-18 | REGN | -0.51 | -0.25 | 2.08 |
| 2025-02-19 | REGN | -0.52 | -0.25 | 2.08 |
| 2025-02-20 | REGN | -0.22 | -0.25 | 2.08 |
| 2025-02-21 | REGN | -0.23 | -0.25 | 2.08 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
12.07
Avg. EPS Est. Current Quarter
9.59
Avg. EPS Est. Next Quarter
10.67
Insider Transactions
-0.23
Institutional Transactions
-0.25
Beta
0.27
Average Sales Estimate Current Quarter
3429
Average Sales Estimate Next Quarter
3611
Fair Value
1016.47
Quality Score
99
Growth Score
84
Sentiment Score
94
Actual DrawDown %
42.2
Max Drawdown 5-Year %
-44.8
Target Price
947.04
P/E
18.29
Forward P/E
15.05
PEG
2.84
P/S
5.39
P/B
2.61
P/Free Cash Flow
20.89
EPS
38.29
Average EPS Est. Cur. Y
43.09
EPS Next Y. (Est.)
47.07
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
31.07
Relative Volume
0.81
Return on Equity vs Sector %
-4.2
Return on Equity vs Industry %
11.4
EPS 1 7Days Diff
-0.8
EPS 1 30Days Diff
-1.87
EBIT Estimation
34.2
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15106
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGN – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGN – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGN – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGN – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading